This site is intended for US healthcare professionals.
Video resources to bring a real-world perspective
Video resources to bring a real-world perspective
Please see Important Safety Information below or full Prescribing Information.
Pedro C Barata, MD, MSc offers insights and perspectives about FOTIVDA in this informational video.
Overview of FOTIVDA
Pedro C Barata, MD, MSc, Director of GU Medical Oncology Research Program at University Hospitals Seidman Cancer Center and Associate Professor of Medicine at Case Western Reserve University offers insights and perspectives about FOTIVDA in this informational video.
Have more questions?
Reach out to an AVEO Oncology Account Manager.
References: 1. FOTIVDA (tivozanib) [package insert]. Boston MA: Aveo Pharmaceuticals Inc, March 2021. 2. Rini BI, Pal SK, Escudier BJ, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomized, controlled, open label study. Lancet Oncol. 2020;21(1):95-104.